Jubilant Biosys Ltd., Bengaluru based subsidiary of Jubilant Life Sciences Ltd, an integrated pharma & life sciences company of India and Norgine, a leading European speciality pharmaceutical company have entered into a discovery partnership. The collaboration, spanning an initial period of 3 years will provide a platform for Norgine to develop multiple targets utilising Jubilant Biosys integrated drug discovery platform targeting gastrointestinal diseases.

Under the terms of the agreement Jubilant shall deliver preclinical candidates to Norgine who will own all rights to further development and commercialisation of the candidates. Norgine is active in research and development and currently has products in various stages of clinical development. It manufactures most of its own products in Hengoed, UK and Dreux, France.

Commenting on the collaboration, Mosur, president and CEO, Global Drug Discovery and Development at Jubilant, said: “Jubilant is very pleased to partner with Norgine, a very successful European speciality pharmaceutical company. We are confident our “accelerated discovery” platform will enable Norgine’s quest for novel and optimal therapies in delivering affordable care to the unmet needs of patients in Europe and worldwide in the area of gastrointestinal disease”.

Ian Cox, vice president of Pharmaceutical & Preclinical Development at Norgine said: “We are delighted to be collaborating with Jubilant, a company with a track record in these types of discovery programmes, and we genuinely look forward to a productive and fruitful relationship”.

Norgine is an independent, successful European speciality pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2010, Norgine’s net product sales were €258 million. The company employs over 1,200 people. Norgine’s focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care.

Norgine currently markets a range of products in various markets in its key therapeutic areas e.g., MOVICOL for the treatment of constipation and faecal impaction, MOVIPREP a bowel cleansing preparation, KLEAN-PREP for bowel preparation prior to colonoscopy, XIFAXAN for the treatment of travellers diarrhoea and ORAMORPH for the treatment of moderate to severe pain associated with cancer.